TY - JOUR
T1 - Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients
AU - Klepstad, P
AU - Fladvad, T
AU - Skorpen, F
AU - Bjordal, K
AU - Caraceni, A
AU - Dale, O
AU - Davies, A
AU - Kloke, M
AU - Lundström, S
AU - Maltoni, M
AU - Radbruch, L
AU - Sabatowski, R
AU - Sigurdardottir, V
AU - Strasser, F
AU - Fayers, P M
AU - Kaasa, S
AU - European Palliative Care Research Collaborative (EPCRC)
AU - Sjøgren, Per
N1 - Copyright © 2011 International Association for the Study of Pain. All rights reserved.
PY - 2011
Y1 - 2011
N2 - Cancer pain patients need variable opioid doses. Preclinical and clinical studies suggest that opioid efficacy is related to genetic variability. However, the studies have small samples, findings are not replicated, and several candidate genes have not been studied. Therefore, a study of genetic variability with opioid doses in a large population using a confirmatory validation population was warranted. We recruited 2294 adult European patients using a World Health Organization (WHO) step III opioid and analyzed single nucleotide polymorphisms (SNPs) in genes with a putative influence on opioid mechanisms. The patients' mean age was 62.5 years, and the average pain intensity was 3.5. The patients' primary opioids were morphine (n=830), oxycodone (n=446), fentanyl (n=699), or other opioids (n=234). Pain intensity, time on opioids, age, gender, performance status, and bone or CNS metastases predicted opioid dose and were included as covariates. The patients were randomly divided into 1 development sample and 1 validation sample. None of 112 SNPs in the 25 candidate genes OPRM1, OPRD1, OPRK1, ARRB2, GNAZ, HINT1, Stat6, ABCB1, COMT, HRH1, ADRA2A, MC1R, TACR1, GCH1, DRD2, DRD3, HTR3A, HTR3B, HTR2A, HTR3C, HTR3D, HTR3E, HTR1, or CNR1 showed significant associations with opioid dose in both the development and the validation analyzes. These findings do not support the use of pharmacogenetic analyses for the assessed SNPs to guide opioid treatment. The study also demonstrates the importance of validating findings obtained in genetic association studies to avoid reporting spurious associations as valid findings. To elicit knowledge about new genes that influence pain and the need for opioids, strategies other than the candidate gene approach is needed.
AB - Cancer pain patients need variable opioid doses. Preclinical and clinical studies suggest that opioid efficacy is related to genetic variability. However, the studies have small samples, findings are not replicated, and several candidate genes have not been studied. Therefore, a study of genetic variability with opioid doses in a large population using a confirmatory validation population was warranted. We recruited 2294 adult European patients using a World Health Organization (WHO) step III opioid and analyzed single nucleotide polymorphisms (SNPs) in genes with a putative influence on opioid mechanisms. The patients' mean age was 62.5 years, and the average pain intensity was 3.5. The patients' primary opioids were morphine (n=830), oxycodone (n=446), fentanyl (n=699), or other opioids (n=234). Pain intensity, time on opioids, age, gender, performance status, and bone or CNS metastases predicted opioid dose and were included as covariates. The patients were randomly divided into 1 development sample and 1 validation sample. None of 112 SNPs in the 25 candidate genes OPRM1, OPRD1, OPRK1, ARRB2, GNAZ, HINT1, Stat6, ABCB1, COMT, HRH1, ADRA2A, MC1R, TACR1, GCH1, DRD2, DRD3, HTR3A, HTR3B, HTR2A, HTR3C, HTR3D, HTR3E, HTR1, or CNR1 showed significant associations with opioid dose in both the development and the validation analyzes. These findings do not support the use of pharmacogenetic analyses for the assessed SNPs to guide opioid treatment. The study also demonstrates the importance of validating findings obtained in genetic association studies to avoid reporting spurious associations as valid findings. To elicit knowledge about new genes that influence pain and the need for opioids, strategies other than the candidate gene approach is needed.
KW - Adaptor Proteins, Signal Transducing
KW - Analgesics, Opioid
KW - Chi-Square Distribution
KW - Europe
KW - Female
KW - Genome-Wide Association Study
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasms
KW - Opioid-Related Disorders
KW - Pain
KW - Pain Measurement
KW - Polymorphism, Single Nucleotide
KW - Receptors, Opioid
KW - Signal Transduction
U2 - 10.1016/j.pain.2011.01.040
DO - 10.1016/j.pain.2011.01.040
M3 - Journal article
C2 - 21398039
SN - 0304-3959
VL - 152
SP - 1139
EP - 1145
JO - Pain
JF - Pain
IS - 5
ER -